Blinatumomab for Minimal Residual Disease Before Hematopoietic Stem Cell Transplantation With Pediatric B-cell Precursor Acute Lymphoblastic Leukemia
Latest Information Update: 11 Mar 2022
At a glance
- Drugs Blinatumomab (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
Most Recent Events
- 20 Feb 2022 Status changed from not yet recruiting to recruiting.
- 09 Apr 2021 Planned initiation date changed from 1 Mar 2021 to 1 May 2021.
- 02 Mar 2021 Planned initiation date changed from 1 Dec 2020 to 1 Mar 2021.